Viroj Wiwanitkit. Show Affiliations »
Abstract
Entities: Chemical
Mesh： See more » Angiogenesis Inhibitors/administration & dosageAngiogenesis Inhibitors/economicsAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/economicsAntibodies, Monoclonal, HumanizedAptamers, Nucleotide/administration & dosageAptamers, Nucleotide/economicsChoroidal Neovascularization/drug therapyChoroidal Neovascularization/economicsChoroidal Neovascularization/physiopathologyCost-Benefit AnalysisCosts and Cost AnalysisHealth Care CostsHealth Services ResearchHumansMacular Degeneration/drug therapyMacular Degeneration/economicsMacular Degeneration/physiopathologyQuality-Adjusted Life YearsRanibizumabVisual Acuity/physiology
Substances： See more » Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotidepegaptanibRanibizumab
Year: 2010 PMID： 20424851 DOI： 10.1007/s00417-010-1390-1
Source DB: PubMed Journal: Graefes Arch Clin Exp Ophthalmol ISSN： 0721-832X Impact factor: 3.117